FDA Warning Letter: Major CGMP, Stability, OOS and Storage Violations The FDA warning letter issued highlights identifies significant Current Good Manufacturing Practice (CGMP) deficiencies observed during an FDA inspection conducted from March 31 to April 3, 2026, at the firm’s drug manufacturing facility in Chatsworth, California. The FDA warning letter states that the firm’s methods, … Read more
FDA Warning Letter: Major CGMP, Aseptic Processing and Sterile Manufacturing Violations This FDA warning letter identifies significant Current Good Manufacturing Practice (CGMP) deficiencies involving the manufacture of sterile injectable drug products. FDA determined that the firm’s methods, facilities, controls, and quality systems did not adequately conform to CGMP requirements under 21 CFR Parts 210 and … Read more
FDA Warning Letter: Major CGMP, OOS Investigation and Quality System Violations – FDA Warning Letter Summary This FDA warning letter identifies significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals under 21 CFR Parts 210 and 211. FDA determined that the firm’s manufacturing methods, facilities, and controls did not conform to CGMP requirements … Read more
FDA Warning Letter: Major CGMP Violations in Drug Manufacturing and Quality Systems This FDA warning letter identifies significant violations of Current Good Manufacturing Practice (CGMP) requirements at a foreign drug manufacturing facility registered with the U.S. Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. The FDA warning letter was issued … Read more
FDA Warning Letter: Major CGMP, Quality System and OTC Drug Violations This FDA warning letter identifies significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals under 21 CFR Parts 210 and 211. FDA concluded that the firm’s manufacturing, processing, packing, and holding controls did not conform to CGMP requirements, resulting in drug … Read more
FDA Warning Letter An FDA warning letter is a serious regulatory communication that identifies significant violations of FDA requirements and allows a pharmaceutical manufacturer to take corrective action. In this case, the FDA warning letter identifies three major CGMP deficiencies related to finished-product testing, incoming material controls, and cleaning validation. These findings demonstrate the importance … Read more
Quality Risk Assessment – New Product Introduction: Non-Sterile Ointment / Semi-Solid Product Objective: Identify, assess, and control quality risks associated with the development and manufacture of a new non-sterile ointment/semi-solid pharmaceutical product. 1️⃣ Formulation Risks API–excipient incompatibility API solubility & dispersion Particle size / agglomeration Homogeneity of formulation Physical/chemical instability Preservative effectiveness, where applicable 2️⃣ Manufacturing … Read more
Quality Risk Assessment – New Product Introduction: Non-Sterile Soft Gelatin Capsules Objective: Identify, assess, and control quality risks before commercial manufacture of a new soft gelatin capsule product. 1. Formulation Risks API–excipient incompatibility API degradation / oxidation / hydrolysis Fill viscosity and uniformity Solubility and precipitation Over/under-fill risk 2. Gelatin Shell Risks Gelatin–fill interaction Shell thickness … Read more
Quality Risk Assessment for Solid Oral Dosage Forms for New Product Introduction OBJECTIVEEvaluate and control quality risks before introducing a new oral liquid product to ensure patient safety, product quality, process robustness, and GMP compliance. KEY RISK AREAS 1️⃣ Product & Formulation API–excipient compatibility Solubility / suspension characteristics CQAs: assay, pH, viscosity, microbial limits Preservative … Read more
Quality Risk Assessment for Solid Oral Dosage Forms Non-Sterile Solid Oral Dosage Forms 🎯 OBJECTIVEEvaluate and control quality risks before introducing a new solid oral dosage product to ensure patient safety, product quality, GMP compliance, and process robustness. 🔍 KEY RISK AREAS 1️⃣ Product & Formulation API/excipient compatibility CQAs: assay, dissolution, content uniformity, impurities API … Read more